Kelley Lauren Coffman, MD, on a Study of 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs

Video
Conference|ASCO Gastrointestinal Cancer Symposium

The hospitalist at Memorial Sloan Kettering Cancer Center highlighted important takeaways from a study which evaluated the use of 177Lu-DOTATATE in patients with well-differentiated, high-grade neuroendocrine tumors.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Study results presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium revealed that investigators observed a meaningful disease control rate among patients with well-differentiated, high-grade neuroendocrine tumors (NETs) who were treated with 177Lu-DOTATATE (Lutathera).

      In an interview with CancerNetwork®, Kelley Lauren Coffman, MD, a hospitalist at Memorial Sloan Kettering Cancer Center, explained what she believes is the greatest takeaway from the study findings.

      Transcription:
      The biggest takeaway point that I emphasized in my presentation at [the meeting] and I’ll emphasize now is that this treatment looks to have a meaningful benefit in these higher-grade, more advanced [NETs]. We observed about a 69% disease control rate in this population, which I think is very encouraging.

      Recent Videos
      Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
      Peritoneal Tumor Treatment Enhanced by Pre-PIPAC-MMC Small Incision Surgery
      Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
      Intraperitoneal Therapy Seeks to Address “Nihilism” Around Peritoneal Mets
      Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
      Data Support Niraparib Combo as First-Line Maintenance in Ovarian Cancer
      ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
      ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
      Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
      Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
      Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
      Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial
      Perioperative Durvalumab Yields Improved Efficacy in NIAGARA Regimen
      Perioperative Durvalumab Yields Improved Efficacy in NIAGARA Regimen
      The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
      The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
      Durvalumab/Chemotherapy Deserving of Consideration in Neoadjuvant MIBC
      Durvalumab/Chemotherapy Deserving of Consideration in Neoadjuvant MIBC
      Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
      42nd Annual Miami Breast Cancer Conference: The Show and After Show
      Related Content
      A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

      A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

      Tim Cortese
      April 2nd 2025
      Article

      Muhammad Talwa Waheed, MD, found that resection after appendectomy should be prioritized in the treatment of patients with appendiceal cancer.

      Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

      Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

      Rahul Banerjee, MD, FACP;Shernan Holtan, MD
      March 3rd 2025
      Podcast

      Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

      HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

      HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

      Tim Cortese
      March 31st 2025
      Article

      Muhammed Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.

      Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

      SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

      Paolo Tarantino, MD;Matteo Lambertini, MD
      January 13th 2025
      Podcast

      Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

      Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

      Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

      Tim Cortese
      March 31st 2025
      Article

      A phase 2 trial presented at SSO met its primary end point by achieving negative margins in 79% of patients with node-negative rectal cancer.

      Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic neuroendocrine tumors.

      FDA Approves Cabozantinib in Pancreatic/Extra-Pancreatic Neuroendocrine Tumors

      Roman Fabbricatore;Ariana Pelosci
      March 26th 2025
      Article

      Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic and extra-pancreatic neuroendocrine tumors.